Blog

views from the bench masthead

19/4/18
Something A Bit Different

This is a long way off commercialisation and not medchem, indeed only chemistry in a looser sense. Natural enzyme, improved in the lab through biological and molecular modelling understanding, to efficiently catabolise PET plastics.

http://www.bbc.co.uk/news/science-environment-43783631

https://uk.reuters.com/article/us-science-plastic-enzyme/plastic-eating-enzyme-holds-promise-in-fighting-pollution-scientists-idUKKBN1HN2OZ

border

18/4/18
News on BLU-667

A small molecule, structure unknown, RET inhibitor, reports positive phase I clinical trial, in cancer patients.

https://www.fiercebiotech.com/biotech/blueprint-reports-promising-phase-1-data-ret-altered-tumors-aacr?mkt_

More details and structure can be found in this open access article

http://cancerdiscovery.aacrjournals.org/content/early/2018/04/12/2159-8290.CD-18-0338?utm_source=olf&utm_medium=socialatAM&utm_campaign=180338

border

17/4/18
News on ATX-GD-59

A positive antibody therapy, in immune disorder Graves disease, in a phase I clinical trial.

https://www.fiercebiotech.com/biotech/apitope-preps-graves-disease-drug-for-phase-2-after-positive-trial?mkt_

border

9/4/18
Classification on Tumours

I blogged on this twice in 2016, now in mainstream media.

http://www.bbc.co.uk/news/health-43659760

https://www.telegraph.co.uk/news/2018/04/07/cancer-textbook-should-rewritten-classify-cancers-type-not-start/

border

4/4/2018
News on Cyramza

A successful trial in Liver cancer, for Cyramza (an antibody), is reported.

https://uk.reuters.com/article/us-lilly-study/lillys-cyramza-succeeds-in-late-stage-liver-cancer-trial-idUKKCN1HB1F8

border

28/3/2018
News on Bempedoic Acid

Bempedoic acid lowers LDL cholesterol in add-on therapy

https://www.fiercebiotech.com/biotech/esperion-s-ldl-drug-flies-through-phase-2-as-add-treatment?mkt_

Structure can be found on this link:

https://pubchem.ncbi.nlm.nih.gov/compound/etc-1002#section=Top

border

21/3/2018
News on Etrasimod

Etrasimod, a sphingosine 1-phosphate receptor inhibitor, phase II data in ulcerative colitis.

https://www.fiercebiotech.com/biotech/midstage-success-prompts-arena-to-push-bowel-disease-drug-etrasimod-into-phase-3?mkt_

Structure can be found on this link:

https://pubchem.ncbi.nlm.nih.gov/compound/Etrasimod#section=Top

border

20/3/2018
News on Rezafungin

Anti-fungal, Rezafungin, has a reported positive Phase II clinical study as an IV formulation. A literal heavy weight drug, at MW1226.

https://www.fiercebiotech.com/biotech/cidara-leaps-as-antifungal-drug-aces-phase-2?mkt_

Structure can be found on this link

http://www.chemspider.com/Chemical-Structure.58826030.html

border

19/3/2018
News on stem Cells in MS

Multiple sclerosis (MS) is a disease where the immune system goes rogue and attacks the nerve cells. This report on how stem cell therapy could help MS patients and its costs versus conventional drugs.

http://www.bbc.co.uk/news/health-43435868

border

15/3/2018
News on PRX-106 / OPRX-106

An unusual biological drug under investigation in ulcerative colitis, human tumour necrosis factor receptor II fused to an IgG1 Fc domain expressed in a plant cell. The whole plant cell is administered and protects the drug on its passage through the GI tract.

https://www.fiercebiotech.com/biotech/protalix-oral-anti-tnf-drug-hits-mark-phase-2-ulcerative-colitis-trial?mkt_

http://protalix.com/products/prx-106-oral-antitnf/

border

14/3/2018
News on Xeljanz (Tofacitinib)

JAK inhibitor, Tofacitinib, could benefit patients with ulcerative colitis, according to this report.

https://uk.reuters.com/article/us-pfizer-fda/fda-panel-backs-pfizers-xeljanz-as-bowel-disease-treatment-idUKKCN1GK2TW

Structure can be found on this link:

https://en.wikipedia.org/wiki/Tofacitinib

border

12/3/2018
News on Mavacamten

News on a positive phase II readout for Mavacanten in obstructive hypertrophic cardiomyopathy.

https://www.fiercebiotech.com/biotech/myokardia-delivers-midstage-trial-revs-up-for-phase-3?mkt_

Structure can be found on this link:

https://chem.nlm.nih.gov/chemidplus/rn/1642288-47-8

border

9/3/2018
News on Evobrutinib

BTK inhibitor, evobrutinib, is reported to have had a positive clinical phase IIa outcome in multiple sclerosis.

https://www.fiercebiotech.com/biotech/merck-kgaa-btk-inhibitor-beats-placebo-phase-2-multiple-sclerosis-trial?mkt_

Structure can be found on this link:

https://pubchem.ncbi.nlm.nih.gov/compound/71479709#section=Top

border

7/3/2018
News on RG6042

News on an antisense drug, in a combined phase I/II clinical study, of RG6042, in Huntingdon’s Disease.

https://www.fiercebiotech.com/biotech/roche-ionis-hail-huntington-s-success-plan-pivotal-trial?mkt_

border

5/3/2018
News on RPL-554

RPL-554 is a dual PDE3/PDE4 inhibitor under investigation in COPD and CF. Here are some reports of a clinical IIa study in CF patients.

https://www.fiercebiotech.com/biotech/verona-jumps-as-midphase-cystic-fibrosis-data-dial-up-hopes?mkt_

Structure can be found on this link:

https://en.wikipedia.org/wiki/RPL-554

border

27/2/2018
Screening Oncology Drugs with Mini-tumours

Identifying a tumour by mutation, rather than tissue of origin, has been a step forward in treating cancer. Here a biopsy sample has been grown into mini-tumours and then incubated with various anti-cancer drugs to identify the most efficacious. Very much how we used to grow bacteria in petri dishes and then introduce impregnated discs of antibiotics to identify an efficacious drug for that pathogen.

http://www.bbc.co.uk/news/health-43154878

border

23/2/2018
News on Semaglutide

A long acting GLP-1 agonist, Semaglutide, previously blogged in Aug 2017, now reports on phase III clinical trial readout.

https://www.fiercepharma.com/pharma/novo-trumpets-first-ph3-semaglutide-results-does-lilly-need-to-worry-yet?mkt_

Structure can be found on this link:

https://en.wikipedia.org/wiki/Semaglutide

border

14/2/2018
News on Antibiotics

A new class of antibiotic is reported in main stream media. Macrocyclic in nature and 4 carboxylic acids, to me it does not look like your typical “oral drug”.

http://www.bbc.co.uk/news/health-43032602

Structure can be found on this link:

https://en.wikipedia.org/wiki/Malacidin

border

9/2/2018
News on MGL-3196

Information on MGL-3196, in phase II clinical trial, for heterozygous familial hypercholesterolemia (HeFH). Reports of significant reduction in LDL cholesterol.

https://www.fiercebiotech.com/biotech/madrigal-says-nash-drug-also-works-genetic-cholesterol-disorder?mkt_

Structure can be found on this link:

https://pubchem.ncbi.nlm.nih.gov/compound/mgl-3196#section=Top

border

8/2/2018
News on a Drug Combo Binimetinib and Encorafenib

A positive report on a drug combination to treat melanoma. The drugs are MEK inhibitor (Binimetinib) and BRAF inhibitor (Encorafenib).

https://www.fiercebiotech.com/biotech/array-s-encorafenib-binimetinib-beats-roche-s-zelboraf-phase-3?mkt_

Structure can be found on these links:

https://pubchem.ncbi.nlm.nih.gov/compound/10288191#section=Top

https://pubchem.ncbi.nlm.nih.gov/compound/50922675#section=Top

border

7/2/2018
News on Ubrogepant

Ubrogepant is a calcitonin gene-related peptide (CGRP) type 1 receptor antagonist for migraine.

https://www.fiercebiotech.com/biotech/allergan-cgrp-drug-hits-goals-phase-3-migraine-trial?mkt_

Structure can be found on this link:

https://pubchem.ncbi.nlm.nih.gov/compound/Ubrogepant#section=Top

border

1/2/2018
News on Balovaptan

Balovaptan, a vasopressin V1a receptor antagonist, is currently in phase II trials, to treat autism spectrum disorders.

https://www.fiercebiotech.com/biotech/roche-bags-breakthrough-status-for-autism-hope-balovaptan?mkt_

Structure can be found on this link:

https://en.wikipedia.org/wiki/RG7314

border

30/1/2018
News on Revefenacin

Revefenacin, a nebulised long acting muscarinic antagonist (LAMA), has been accepted for review by the FDA, to treat COPD.

https://www.medscape.com/viewarticle/890044

Structure can be found on this link:

https://pubchem.ncbi.nlm.nih.gov/compound/Revefenacin#section=Top

border

29/1/2018
News on Lutathera

FDA approves radioactive drug, Lutathera, for gastroenteropancreatic neuroendocrine tumours.

https://uk.reuters.com/article/us-advanced-accelerator-fda/fda-clears-radioactive-drug-for-cancer-that-killed-steve-jobs-idUKKBN1FF29K

Structure can be found on these links:

https://chem.nlm.nih.gov/chemidplus/rn/437608-50-9

https://pubchem.ncbi.nlm.nih.gov/compound/121225499#section=Top

border

26/1/2018
News on Ezutromid

Early readout on a phase II trial of Ezutromid in Duchenne Muscular Dystrophy. Route of administration is not given; however, vendors report oral bioavailable.

https://www.fiercebiotech.com/biotech/summit-therapeutics-unveils-encouraging-early-data-for-duchenne-drug?mkt_

Structure can be found on this link:

https://pubchem.ncbi.nlm.nih.gov/compound/Ezutromid#section=Top

border

22/1/2018
Cancer Screening with a Blood Test

It is well appreciated that the earlier you can detect and treat cancer, the better the prognosis. So whilst not a new drug, this blood test to potential detect 16 mutated genes and 8 circulating proteins as indicators of cancer is exciting.

http://www.bbc.co.uk/news/health-42736764

border


18/1/2018
News on Kymriah

Novartis entry in the CAR-T area is Kymriah; patients own T-cells are removed, modified and then returned to fight cancer.

https://uk.reuters.com/article/us-novartis-fda-kymriah/novartiss-kymriah-wins-speedy-reviews-in-u-s-europe-idUKKBN1F60KT

border

17/1/2018
Kinases

Derek Lowe is a blog I read quite often. Here he gives his perspective on Kinases and a review article covering the whole area comprehensively (subscription required). As a medicinal chemist, you like your potential drug to be selective for your target only. You only know about selectivity when you go and look for it; and only quote selectivity over the enzymes/receptors screened.

http://blogs.sciencemag.org/pipeline/archives/2018/01/16/the-landscape-of-kinase-inhibitors

border

10/1/2018
News on BGB324

Measured response to AXL inhibitor BGB324 (bemcentinib) clinical data disclosure.

https://www.fiercebiotech.com/biotech/bergenbio-s-axl-inhibitor-clears-early-efficacy-test-nsclc?mkt_

Structure can be found on this link:

https://pubchem.ncbi.nlm.nih.gov/compound/r428#section=Top

border

5/1/2018
News on EOS200271

This is an interim readout, on a phase I trial. What grabbed my interest is the small chemical structure and that it is racemic. Presumably what could be a chiral centre, racemises rapidly, negating isolation as a single enantiomer.

https://www.fiercebiotech.com/biotech/pfizer-drops-iteos-ido1-cancer-drug-due-to-lack-efficacy?mkt_

Structure can be found on this link:

https://pubchem.ncbi.nlm.nih.gov/compound/23063810#section=Top

border

4/1/2018
New Drugs Approved by FDA in 2017

Headline figure shows more new medicines getting to patients in 2017. However, many are for small disease populations.

https://uk.reuters.com/article/us-pharmaceuticals-approvals/new-drug-approvals-hit-21-year-high-in-2017-idUKKBN1ER0P7

border

3/1/2018
News on Cabometyx

Cabozantinib, a poly kinase inhibiter, now approved in renal cancers.

https://www.fiercepharma.com/regulatory/exelixis-soars-early-expanded-approval-for-kidney-cancer-drug?mkt_

Structure can be found on this link:

https://en.wikipedia.org/wiki/Cabozantinib

border

2/1/2018
News on Steglatro (ertugliflozin)

Steglatro is a SGLT2 inhibitor, to treat type II diabetes, whose mode of action is to excrete excess sugars in urine.

https://www.reuters.com/article/us-merck-co-pfizer-diabetes/u-s-fda-approves-new-diabetes-drug-from-merck-and-pfizer-idUSKBN1EE2QT

Structure can be found on this link:

https://pubchem.ncbi.nlm.nih.gov/compound/Ertugliflozin#section=To

border

Read earlier blog posts from 2017, 2016 and 2015 by clicking here.